Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 215

1.

Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?

Páramo JA, Rodríguez JA, Beloqui O, Orbe J.

Curr Drug Targets Cardiovasc Haematol Disord. 2005 Aug;5(4):303-11. Review.

PMID:
16101563
2.

[Cyclooxygenase-2: a new therapeutic target in atherosclerosis?].

Páramo JA, Beloqui O, Orbe J.

Med Clin (Barc). 2006 May 27;126(20):782-6. Review. Spanish.

PMID:
16792983
3.

Cyclooxygenase isoforms and atherosclerosis.

Belton O, Fitzgerald DJ.

Expert Rev Mol Med. 2003 Mar 7;5(9):1-18. Review.

PMID:
14987412
4.

Clinical pharmacology of selective COX-2 inhibitors.

Capone ML, Tacconelli S, Sciulli MG, Patrignani P.

Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. Review.

PMID:
14552704
5.

Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.

Howard PA, Delafontaine P.

J Am Coll Cardiol. 2004 Feb 18;43(4):519-25. Review.

6.

Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.

Niederberger E, Manderscheid C, Grösch S, Schmidt H, Ehnert C, Geisslinger G.

Biochem Pharmacol. 2004 Jul 15;68(2):341-50.

PMID:
15194006
7.

Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

Beloqui O, Páramo JA, Orbe J, Benito A, Colina I, Monasterio A, Díez J.

Eur Heart J. 2005 Jan;26(2):153-8. Epub 2004 Nov 30.

PMID:
15618071
8.

Cardiovascular complications of non-steroidal anti-inflammatory drugs.

Fosslien E.

Ann Clin Lab Sci. 2005 Autumn;35(4):347-85. Review.

PMID:
16254252
9.
10.

Anti-inflammatory drugs in the 21st century.

Rainsford KD.

Subcell Biochem. 2007;42:3-27. Review.

PMID:
17612044
11.

Cyclooxygenase-2 and prostaglandins in articular tissues.

Martel-Pelletier J, Pelletier JP, Fahmi H.

Semin Arthritis Rheum. 2003 Dec;33(3):155-67. Review.

PMID:
14671726
12.

Selective COX-2 inhibitors and risk of myocardial infarction.

Krotz F, Schiele TM, Klauss V, Sohn HY.

J Vasc Res. 2005 Jul-Aug;42(4):312-24. Epub 2005 Jun 20. Review.

PMID:
15976506
13.

[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].

Burdan F, Korobowicz A.

Pol Merkur Lekarski. 2003 Apr;14(82):352-5. Review. Polish.

PMID:
12868201
14.

Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis.

Belton OA, Duffy A, Toomey S, Fitzgerald DJ.

Circulation. 2003 Dec 16;108(24):3017-23. Epub 2003 Nov 24.

15.

Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?

Hersh EV, Lally ET, Moore PA.

Curr Med Res Opin. 2005 Aug;21(8):1217-26. Review.

PMID:
16083531
16.

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

Dajani EZ, Islam K.

J Physiol Pharmacol. 2008 Aug;59 Suppl 2:117-33. Review.

17.

Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability.

Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A.

Circulation. 2001 Aug 21;104(8):921-7.

18.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

19.

Cancer prevention: a new era beyond cyclooxygenase-2.

Rigas B, Kashfi K.

J Pharmacol Exp Ther. 2005 Jul;314(1):1-8. Epub 2005 Apr 1. Review.

20.

Coxibs--beyond the GI tract: renal and cardiovascular issues.

DeMaria AN, Weir MR.

J Pain Symptom Manage. 2003 Feb;25(2 Suppl):S41-9. Review.

PMID:
12604156

Supplemental Content

Support Center